@article{10.1172/JCI142765, author = {Nidhi S. Dey AND Sujai Senaratne AND Vijani Somaratne AND Nayani P. Madarasinghe AND Bimalka Seneviratne AND Sarah Forrester AND Marcela Montes de Oca AND Luiza Campos Reis AND Srija Moulik AND Pegine B. Walrad AND Mitali Chatterjee AND Hiro Goto AND Renu Wickremasinghe AND Dimitris Lagos AND Paul M. Kaye AND Shalindra Ranasinghe}, journal = {The Journal of Clinical Investigation}, publisher = {The American Society for Clinical Investigation}, title = {Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis}, year = {2024}, month = {3}, volume = {131}, url = {https://www.jci.org/articles/view/142765}, abstract = {Cutaneous leishmaniasis (CL) is caused by Leishmania donovani in Sri Lanka. Pentavalent antimonials (e.g., sodium stibogluconate [SSG]) remain first-line drugs for CL with no new effective treatments emerging. We studied whole blood and lesion transcriptomes from Sri Lankan patients with CL at presentation and during SSG treatment. From lesions but not whole blood, we identified differential expression of immune-related genes, including immune checkpoint molecules, after onset of treatment. Using spatial profiling and RNA-FISH, we confirmed reduced expression of programmed death-ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1) proteins on treatment in lesions of a second validation cohort and further demonstrated significantly higher expression of these checkpoint molecules on parasite-infected compared with noninfected lesional CD68+ monocytes and macrophages. Crucially, early reduction in PD-L1 but not IDO1 expression was predictive of rate of clinical cure (HR = 4.88) and occurred in parallel with reduction in parasite load. Our data support a model whereby the initial anti–leishmanial activity of antimonial drugs alleviates checkpoint inhibition on T cells, facilitating immune-drug synergism and clinical cure. Our findings demonstrate that PD-L1 expression can be used as a predictor of rapidity of clinical response to SSG treatment in Sri Lanka and support further evaluation of PD-L1 as a host-directed therapeutic in leishmaniasis.}, number = {22}, doi = {10.1172/JCI142765}, url = {https://doi.org/10.1172/JCI142765}, }